Rockville, MD -- (SBWIRE) -- 12/15/2018 -- Leprosy is a chronic infectious disease caused by Mycobacterium leprae. Leprosy is also known as Hansen's disease. It affects the skin, mucosal surfaces of the upper respiratory tract, the peripheral nerves and the eyes. Leprosy can occur in people of all ages, from infants to the elderly. The exact transmission of the disease is not known, but it is strongly believed that leprosy is transferred from a leprosy patient to a healthy person. Delayed diagnosis of leprosy is likely to cause some serious complications such as muscle weakness, erectile dysfunction, kidney failure, blindness and others. The best way to prevent leprosy is to avoid contact with infected and untreated people. Leprosy is a curable disease and various drugs are available in the market for the treatment of leprosy. One of the treatments for leprosy is Multidrug Therapy (MDT), which involves the use of a combination of drugs. The World Health Organization recommends a combination of rifampicin, clofazimine and dapsone drugs for leprosy treatment.

Get Free Exclusive Sample Copy of This Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=1304

Leprosy Treatment Market: Drivers and Restraints

Increasing prevalence of skin diseases is the primary factor expected to drive the leprosy treatment market over the forecast period. The prevalence of skin diseases, such as leprosy and psoriasis, has become common in some of the counties of Asia-Pacific, which is responsible for the robust growth of the market. Rising government initiatives and favourable reimbursement scenario for these treatments is expected to propel the leprosy treatment market. On other hand, the high cost of drugs and lack of awareness among people is expected to restrain market growth to a certain extent. In addition, the stringent regulatory requirements of FDA for the approval of drugs is also expected to be responsible for the sluggish growth of the leprosy treatment market over the forecast period.

Leprosy Treatment Market: Overview

Leprosy Treatment market is expected to witness exponential growth over the forecast period owing rising patient pool of leprosy in Asia-Pacific. According to WHO, the prevalence of this disease in 2015 was 176 cases per 10000 people. About 60% of the world's leprosy patients live in India. Therefore, India is a major market worldwide for the treatment of this disease. Antibacterial drugs are commonly prescribed by physicians for leprosy treatment, therefore, by drugs class, the antibacterial segment is expected to gain maximum market share over the forecast period. The most common antibacterial drugs prescribed for leprosy treatment are dapsone, rifampin, clofazimine, ofloxacin and minocycline. Among distribution channels, online pharmacies is the fastest-growing segment due to the increasing adoption of e-commerce throughout the globe.

Leprosy Treatment Market: Regional Outlook

Geographically, the global leprosy treatment market is segmented into North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East & Africa (MEA). Asia-Pacific is expected to gain maximum market share in terms of revenue owing to the high patient pool of leprosy in India and China. The APEJ is followed by Japan and Latin America owing to increasing awareness among patients about leprosy treatment options available in these regions. MEA is expected to grow at a faster rate as compared to other regions due to rising government initiatives for the treatment of this disease. North America, Western Europe and Eastern Europe are the least lucrative markets for leprosy treatment as a very small number of patients in these regions suffer from this disease owing to high standards of living and increased personal hygiene.

Ask For Customized Report @ https://www.factmr.com/connectus/sample?flag=RC&rep_id=1304

Leprosy Treatment Market: Key Players

Some of the key players operating in the global leprosy treatment market are Pfizer Inc., Bristol-Myers Squibb and Company, Eli Lily and Company, Johnson & Johnson Services Inc., GlaxoSmithKline PLC, Bayer AG, Cadila Pharmaceuticals, Sanofi S.A., Novartis AG, Teva Pharmaceutical Industries Ltd., Macleods Pharmaceuticals and Merck & Co., Inc.

Report Overview at https://www.factmr.com/report/1304/leprosy-treatment-market

About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: www.factmr.com/